With gene editing tools becoming advanced enough to realise therapeutic potential, decision-makers working in academia and pharma are looking to consolidate their techniques to facilitate disease modelling, drug development and clinical studies.
This Year's Event Includes...
Over 800 attendees representing internationally renowned academic institutions, research institutes and hospitals as well as global pharmaceutical organisations and leading biotech companies.
Over 30 case studies, presentations, panel discussions focused on the key issues in advanced genome editing technologies, utilizing gene editing in drug discovery & development and therapeutics case studies from the areas of cystic fibrosis, neurodegenerative diseases and immunological and congenital disorders.
PLUS interactive opportunities including:
- Panel Discussions
- Pre-Event Webinars
- Pre-Event Speaker Q&As and Spotlights
Agenda at a Glance
- Advancements in genome editing tools
- New technologies
- Developing novel CAS systems
- Workshop: Comparison of Different CAS-es: Which Works Best for In Vivo?
- Therapeutic case studies
- Specificity and safety considerations
- Ethical and legal issues of human germline editing
- CHO cell engineering for biotherapeutics production
- Alternative applications of genome editing
- Ensuring quality and stability
- Model-based CHO Cell Engineering
- Process optimisation of CHO Cell Lines
- In vivo genome editing as a therapeutics approach in pharma
- Target identification & validation
- Implementing gene editing systems for drug screening and development
- Gene-edited Cell Therapy
- T-Cell engineering using CRISPR Cas and TALEN